# EDGAR Filing Document

**Accession Number:** 0001088856
**File Stem:** 0001193125-23-034374
**Filing Date:** 2023-2
**Character Count:** 7862
**Document Hash:** 000299f9b043dbdea2aa23b4974d89a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-034374.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001193125-23-034374

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230213

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CORCEPT THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001088856
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 770487658
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50679
- **FILM NUMBER:** 23614822

**BUSINESS ADDRESS:**
- **STREET 1:** 149 COMMONWEALTH DRIVE
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 650.688.8803

**MAIL ADDRESS:**
- **STREET 1:** 149 COMMONWEALTH DRIVE
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 OR 15(d)

#### of The Securities Exchange Act of 1934

#### February 13, 2023

#### Date of Report (date of earliest event reported)

------

## Corcept Therapeutics Incorporated

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-50679** | **77-0487658** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

#### 149 Commonwealth Drive, Menlo Park, CA 94025

#### (Address of Principal Executive Offices) (Zip Code)
(650) 327-3270

#### Registrant's telephone number, including area code

#### Not Applicable

#### (Former name or former address, if changed since last report.)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.001 par value | CORT | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 8.01.** | **Other Events**  |

---

On February 13, 2023, Corcept Therapeutics Incorporated ("Corcept") issued a press release announcing that it has reached a preliminary settlement of all claims in the purported securities class action against Corcept and certain of its executive officers captioned *Melucci v. Corcept Therapeutics Incorporated, et al.*, Case No. 5:19-cv-01372-LHK, which was pending in the United States District Court for the Northern District of California. Under the proposed settlement, Corcept has agreed to make a one-time payment of $14.0 million, which will be covered in full by Corcept's insurers.

The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibits<br>No.** | **Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;99.1 | [Press Release, dated February 13, 2023](d458557dex991.htm) |
| 104.1 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CORCEPT THERAPEUTICS INCORPORATED** | **CORCEPT THERAPEUTICS INCORPORATED** |
| Date: February 13, 2023 | By: | /s/ Atabak Mokari |
|  | Name: | Atabak Mokari |
|  | Title: | Chief Financial Officer and Treasurer |

---

## Exhibit 99.1

**Exhibit 99.1** 

---

| | |
|:---|:---|
| ![LOGO](g458557g0213043917088.jpg) | **CONTACT:**<br> Corcept Therapeutics<br> Investor Relations<br> <u>ir@corcept.com</u><br> www.corcept.com |

---

**CORCEPT THERAPEUTICS ANNOUNCES PRELIMINARY SETTLEMENT** 

**OF PURPORTED SECURITIES CLASS ACTION LITIGATION** 

**MENLO PARK, Calif.** (February 13, 2023) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has reached a preliminary settlement of all claims in the purported securities class action against Corcept and certain of its executive officers captioned *Melucci v. Corcept Therapeutics Incorporated, et al.*, Case No. 5:19-cv-01372-LHK, which was pending in the United States District Court for the Northern District of California. Under the proposed settlement, Corcept has agreed to make a one-time payment of $14.0 million, which will be covered in full by Corcept's insurers.

**About Corcept Therapeutics** 

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators as potential treatments for patients with Cushing's syndrome, ovarian, prostate and adrenal cancer, ALS and liver disease. Corcept's drug Korlym<sup>®</sup> was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing's syndrome.

**Forward-Looking Statements** 

Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These statements include those related to the proposed settlement of the litigation and our insurance coverage. These risks and uncertainties include, but are not limited to, risks that the parties do not reach a final settlement, risks that the United States District Court for the Northern District of California does not approve the proposed settlement, risks that our insurance does not cover the settlement and other risks set forth in Corcept's filings with the Securities and Exchange Commission (the "SEC"), which are available at our website and the SEC's website. We disclaim any intention or duty to update forward-looking statements made in this press release.